The therapeutic landscape of FLT3-mutated AML has been significantly improved with the approval of tyrosine kinase inhibitors (TKIs), which, either as a single agent or in combination with other drugs, offer less aggressive options and, in some cases, avoid the need for cytotoxic chemotherapy [35]. Here, FLT3 is linked to acute myeloid leukemia.